Across TCGA pan-cancer cohorts, ARL2BPP3 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated ARL2BPP3 data layer.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher ARL2BPP3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ARL2BPP3 expression acts as an unfavorable survival marker.
READ, PAAD, and BRCA are the cancer types where ARL2BPP3 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.